A few days after Amgen charted a Phase III map for an up-and-coming cardio drug, the biotech behind its development has decided to cash out.
Arrowhead Pharmaceuticals announced Wednesday morning that it has sold its royalty stake in olpasiran, a siRNA drug developed in-house, to Royalty Pharma for $250 million…
